Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Tafamidis Meglumine"'
Autor:
Damy, Thibaud a, ⁎, 1, Donal, Erwan b, Lairez, Olivier c, Eicher, Jean-Christophe d, Karoubi, Mounira a, Trochu, Jean-Noël e, Inamo, Jocelyn f, Habib, Gilbert g, Roubille, François h, Hagège, Albert i, Morio, Flore e, Cariou, Eve c, Adda, Jérôme j, Algalarrondo, Vincent k, Coste, Agathe l, Bartoli, Mathilde l, Rudant, Jérémie l, Salvi, Lara l, Francou, Bruno m, Guiochon-Mantel, Anne m, Adams, David n, Antoine, Jean-Christophe o, Attarian, Shahram p, Cintas, Pascal q, Morales, Raul Juntas r, Lagrange, Emmeline s, Magy, Laurent t, Mallaret, Martial s, Péréon, Yann u, Petiot, Philippe v, Cauquil, Cécile n, Labeyrie, Céline n, Echaniz-Laguna, Andoni n, Sole, Guilhem w, Tard, Céline x, Oghina, Silvia a, Charron, Philippe y, Slama, Michel k
Publikováno v:
In Rare 2024 2
Autor:
Thibaud Damy, Erwan Donal, Olivier Lairez, Jean-Christophe Eicher, Mounira Karoubi, Jean-Noël Trochu, Jocelyn Inamo, Gilbert Habib, François Roubille, Albert Hagège, Flore Morio, Eve Cariou, Jérôme Adda, Vincent Algalarrondo, Agathe Coste, Mathilde Bartoli, Jérémie Rudant, Lara Salvi, Bruno Francou, Anne Guiochon-Mantel, David Adams, Jean-Christophe Antoine, Shahram Attarian, Pascal Cintas, Raul Juntas Morales, Emmeline Lagrange, Laurent Magy, Martial Mallaret, Yann Péréon, Philippe Petiot, Cécile Cauquil, Céline Labeyrie, Andoni Echaniz-Laguna, Guilhem Sole, Céline Tard, Silvia Oghina, Philippe Charron, Michel Slama
Publikováno v:
Rare, Vol 2, Iss , Pp 100021- (2024)
Aims: We designed a two-part epidemiological study, an observatory for amyloid transthyretin amyloidosis (OBSAMYL). The first objective was to identify and count the number of patients diagnosed with ATTR amyloidosis in participating French centres.
Externí odkaz:
https://doaj.org/article/9befceaceb8743989a4bb9bcd996f3bc
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ekaterina Tankisheva, Melissa O'Gorman, Marla B. Sultan, Vu Le, Steve Riley, Terrell A. Patterson, Qiang Wang, Peter Lockwood
Publikováno v:
Clinical Pharmacology in Drug Development
Tafamidis, a non‐nonsteroidal anti‐inflammatory benzoxazole derivative, acts as a transthyretin (TTR) stabilizer to slow progression of TTR amyloidosis (ATTR). Tafamidis meglumine, available as 20‐mg capsules, is approved in more than 40 countr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16bf176d2b8ca2839df1c35eb7dc5463
https://doi.org/10.1002/cpdd.789
https://doi.org/10.1002/cpdd.789
Publikováno v:
Arquivos de Neuro-Psiquiatria (2021)
A 57-year-old male with previous myocardiopathy, polyneuropathy, bilateral cataract, and autonomic dysfunction had a family history of Familial Amyloid Polyneuropathy (FAP),. When he was 55 years old, he underwent a genetic testing, which detected a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26e3e3ea9865b54e215d34550aa00f99
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021005025204&tlng=en
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021005025204&tlng=en
Publikováno v:
Brain Sciences
Brain Sciences, Vol 10, Iss 952, p 952 (2020)
Brain Sciences, Vol 10, Iss 952, p 952 (2020)
Hereditary amyloid transthyretin (ATTRv) amyloidosis with polyneuropathy is a progressive disease that is transmitted as an autosomal dominant trait and characterized by multiple organ failure, including axonal sensory-motor neuropathy, cardiac invol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9c580d9ace19b5c242ed4499eee7824
http://europepmc.org/articles/PMC7763612
http://europepmc.org/articles/PMC7763612
Publikováno v:
Circulation. 142
Introduction: Tafamidis meglumine, available as 20 mg capsules, is approved in >40 countries for use in early stage, symptomatic transthyretin amyloidosis with polyneuropathy. It is also approved in a growing number of countries as an 80 mg daily dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b2d6b8c5e852c666d4ce5d59959299a
https://doi.org/10.1161/circ.142.suppl_3.12896
https://doi.org/10.1161/circ.142.suppl_3.12896
Autor:
Pablo García-Pavía, Balarama Gundapaneni, Jose Nativi-Nicolau, Peter van der Meer, Marla B. Sultan
Publikováno v:
Circulation. 142
Introduction: Tafamidis meglumine, available as 20 mg capsules, is approved around the world for the treatment of transthyretin amyloidosis in early stage polyneuropathy (20 mg) and more recently in cardiomyopathy (80 mg). A new formulation, tafamidi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28baf2312a74765b5c9c2c4286641125
https://doi.org/10.1161/circ.142.suppl_3.15528
https://doi.org/10.1161/circ.142.suppl_3.15528
Autor:
Mitsuharu Ueda, Tomonori Ishii, Noriko Matsumoto, Ami Takata, Yukio Ando, Yoko Hirano, Yoshiki Sekijima
Publikováno v:
Clinical therapeutics. 42(9)
Purpose An all-case, single-arm, observational, postmarketing surveillance is underway to assess the safety of tafamidis in patients with hereditary transthyretin (ATTRv) amyloidosis with peripheral polyneuropathy, also called transthyretin-type fami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ef4a4c78756ab166517a4271807399f
https://pubmed.ncbi.nlm.nih.gov/32800381
https://pubmed.ncbi.nlm.nih.gov/32800381
Autor:
Hideaki Kanzaki, Yoshiki Sekijima, Yasuhiro Shintani, Chisato Izumi, Hiroyuki Takahama, Yasuhiro Hamatani, Satoshi Yasuda, Masashi Amano, Atsushi Okada, Keiko Ohta-Ogo, Chihiro Shimazaki, Makoto Amaki, Takuya Hasegawa, Masahide Yazaki, Tsuneaki Yoshinaga, Hatsue Ishibashi-Ueda, Yoshiaki Morita
Publikováno v:
ESC Heart Failure. 6:232-236
Tafamidis meglumine, a transthyretin (TTR) stabilizer, is effective in delaying the progression of neuropathy in TTR amyloidosis with Val30Met mutations. However, its efficacy in TTR amyloid cardiomyopathy is not fully elucidated. Herein, we report a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abe6082ad0bc70b06fa22300b2ac6bb9
https://doi.org/10.1002/ehf2.12382
https://doi.org/10.1002/ehf2.12382